Ochre Bio and GSK ink liver disease collaboration

Oxford, UK-based start-up Ochre Bio has announced the start of a multi-year data licence agreement with British pharma major GSK (LSE: GSK).

The partnership will provide GSK with access to Ochre Bio’s computational biology, cellular and perfused human organ platforms to generate proprietary human liver datasets and non-exclusive access to their extensive library of historical liver data.

The collaboration will enable Ochre Bio and GSK to deepen the understanding of liver biology, aligned with GSK’s disease area focus in hepatology, with the aim to further prioritise and accelerate development of medicines to address liver disease. The data will be used by both Ochre Bio and GSK to build better AI models, allowing for fewer, but more precise experiments to aid in target choice.